Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 15, 2009

View Archived Issues

Tafluprost exhibits similar efficacy to latanoprost in phase II and III trials

Vitreosolve effective in clinical trials for PVD induction in diabetic retinopathy

Endoscopic trial in healthy subjects supports favorable efficacy of LT-NS001

FDA approves use of Diamyd vaccine in young children in TrialNet GAD diabetes study

Phase III program of TAK-085 in hypertriglyceridemia initiated in Japan

MRC reports results from international trial of PRO-2000 preventative HIV gel

Emend approved in Japan for chemotherapy-induced nausea and vomiting

ChemGenex and Hospira agree to codevelop omacetaxine for CML

ProMetic Life Sciences meets with FDA on regulatory pathway of PBI-1402

FDA approves Eli Lilly's Zyprexa Relprevv for schizophrenia in adults

Opexa Therapeutics reports securities offering to develop its MS therapy

Alcon to acquire Optonol

Data from phase II and III trials support efficacy of prucalopride in chronic constipation

GMI-1070 shows safety and tolerability in phase I trial in healthy subjects

Phase I data reported for terameprocol in patients with advanced leukemias

CALISTO trial reveals efficacy of fondaparinux in treating superficial vein thrombosis

Roche's ocrelizumab meets primary endpoint in phase III rheumatoid arthritis trial

TGen to test Nerviano Medical Sciences' new anticancer drug NMS-1286937

Pfizer presents FAAH inhibitors for the treatment of pain and other conditions

Vasopressin V1a receptor antagonists identified by sanofi-aventis

Takeda describes ASK1 inhibitors

Vertex describes PI3Kgamma kinase inhibitors for multiple sclerosis therapy

Novel ALK and Bcr-Abl inhibitors claimed by European scientists for cancer therapy

Kowa Pharmaceuticals divests diclofenac products Cambia and PRO-571

Qiagen closes acquisition of SABiosciences

BioAlliance's acyclovir Lauriad achieves endpoints in phase III trial

Ambit Biosciences initiates phase II trial of AC-220 in acute myeloid leukemia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...